结直肠癌患者血清中可溶性CD44和CD44v6水平与肿瘤分期及CD44v6的组织表达无关。

Soluble CD44 and CD44v6 serum levels in patients with colorectal cancer are independent of tumor stage and tissue expression of CD44v6.

作者信息

Weg-Remers S, Hildebrandt U, Feifel G, Moser C, Zeitz M, Stallmach A

机构信息

Department of Internal Medicine II, University of the Saarland, Homburg, Germany.

出版信息

Am J Gastroenterol. 1998 May;93(5):790-4. doi: 10.1111/j.1572-0241.1998.226_a.x.

DOI:10.1111/j.1572-0241.1998.226_a.x

Abstract

OBJECTIVES

Tissue overexpression of CD44 variants, especially CD44v6, and elevated serum concentrations of soluble CD44 variants (sCD44) have been demonstrated in patients with colorectal cancer and several other tumors. Our aim was to evaluate the clinical value of their measurement in colorectal cancer.

METHODS

To examine the suitability of sCD44 and sCD44v6 as tumor markers in colorectal cancer these parameters were analyzed in serum of patients with colorectal cancer, inflammatory bowel disease, chronic renal failure, and controls. Tissue expression of CD44v6 in colorectal carcinomas was investigated by reverse transcriptase-polymerase chain reaction (RT-PCR).

RESULTS

sCD44 and sCD44v6 levels were significantly elevated in most of the patient groups (medians, sCD44: 330-709 ng/ml; sCD44v6: 125-160 ng/ml) compared to controls (sCD44: 346 ng/ml; sCD44v6: 106.5 ng/ml). No difference was seen between colorectal cancer patients of different UICC (Union Internationale Contre le Cancer) stages and between patients with CD44v6-positive or -negative primary tumors.

CONCLUSIONS

sCD44 and sCD44v6 concentrations showed no correlation to tumor burden or CD44v6 tissue expression. Sensitivity and specificity were low, compared to CEA. Therefore, in our view sCD44 and sCD44v6 measurement in screening or follow-up of patients with colorectal cancer is of very little clinical value.

摘要

目的

在结直肠癌和其他几种肿瘤患者中，已证实CD44变体（尤其是CD44v6）的组织过表达以及可溶性CD44变体（sCD44）的血清浓度升高。我们的目的是评估其检测在结直肠癌中的临床价值。

方法

为了检验sCD44和sCD44v6作为结直肠癌肿瘤标志物的适用性，对结直肠癌患者、炎症性肠病患者、慢性肾衰竭患者及对照组的血清进行了这些参数的分析。通过逆转录聚合酶链反应（RT-PCR）研究了CD44v6在结直肠癌组织中的表达。

结果

与对照组（sCD44：346 ng/ml；sCD44v6：106.5 ng/ml）相比，大多数患者组的sCD44和sCD44v6水平显著升高（中位数，sCD44：330 - 709 ng/ml；sCD44v6：125 - 160 ng/ml）。不同国际抗癌联盟（UICC）分期的结直肠癌患者之间以及CD44v6阳性或阴性原发性肿瘤患者之间未见差异。

结论

sCD44和sCD44v6浓度与肿瘤负荷或CD44v6组织表达无相关性。与癌胚抗原（CEA）相比，敏感性和特异性较低。因此，我们认为在结直肠癌患者的筛查或随访中检测sCD44和sCD44v6的临床价值非常小。